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Abstract 
Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular 
carcinoma infecting more than 170 million people.  HCV envelope glycoprotein E2 binds several 
cell surface molecules that act as receptor candidates mediating HCV entry into hepatocytes.  
Peptides derived from human lactoferrin (LF) have been shown to bind HCV E2 protein thereby 
preventing HCV entry in cultured hepatocytes.  In this study, starting from a 33-residue human 
LF-derived peptide, a number of biotin-linked α-peptides were synthesized and investigated for 
their E2 protein binding activity.  E2 protein from HCV genotype 1b was expressed in 293 
human embrionic kidney cells and purified using affinity chromatography.  A biotin-streptavidin 
based binding assay was developed to determine the binding affinity of the synthetic peptides for 
E2 protein.  Two of the peptides bound E2 specifically with submicromolar to low micromolar 
affinity (equilibrium dissociation constant, Kd, of 0.569 and 28.8 M).  Further, these two 
peptides had the highest helical content in solution as observed by CD spectroscopy, suggesting 
that binding affinity increases with increase in helicity.  These results have provided new lead 
peptides for future investigations of HCV entry inhibitors that may provide an interesting 
approach to prevent HCV infectivity. 
 
Abbreviations:  aa, amino acid; CD, circular dichroism; E2, HCV envelope 2 glycoprotein; 
HCV, hepatitis C virus; HOBt, 1-hydroxybenzotriazole; HRPO; horseradish peroxidase; Kd, 
equilibrium dissociation constant; LF, lactoferrin; MALDI-TOFMS, matrix-assisted laser 
desorption ionization time-of-flight mass spectrometry; Ni2+-NTA, nickel(II)-nitrilotriacetic acid; 
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SPPS, solid-phase 
peptide synthesis; TFA, trifluoroacetic acid; TMB, 3,3',5,5'-tetramethylbenzidine 
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Introduction 
Hepatitis C infection has become a “silent pandemic” around the globe infecting more 
than 170 million people worldwide (1).  It is estimated that three to four million persons are 
newly infected each year, 70 percent of whom will develop chronic hepatitis.  HCV is 
responsible for 50–76 percent of all liver cancer cases, and two thirds of all liver transplants in 
the developed world (2).  There is no vaccine for HCV and the current most effective therapies 
for HCV infection involve treatment with pegylated -interferon, either alone or in combination 
with antiviral agent ribavirin.  Although this combination therapy has led to a dramatic 
improvement in the treatment outcome, the low efficacy of the therapy (response rate ~ 50%) 
along with resistance problems, poor tolerability, and high cost necessitates exploration of new 
and more effective therapies (3, 4). 
Currently, the principal targets of new antivirials are the NS3 protease and the RNA-
dependent RNA polymerase (RdRp) (5).  More recently, cyclophilin inhibitors that target host-
virus interactions have also gained attention (6).  Several molecules inhibiting these targets are 
currently in either preclinical or clinical stages.  The early steps of the HCV life cycle are also 
attractive targets for novel therapies, such as virus attachment to host cells, internalization of the 
virus-receptor complex, and the fusion that releases the nucleocapsid into the cytoplasm.  
However, the later targets have been less explored (7, 8).  Although the entry mechanism of 
HCV remains unclear, it has become evident that the initiation of the infection takes place by 
association of the viral envelope protein E2 with specific cell-surface receptor(s) (9).  Many 
groups have demonstrated that the truncated soluble versions of E2 bind specifically to human 
cells.  This glycoprotein is used to identify interaction with cell-surface receptors, such as, CD81, 
SR-B1, LDL, DC-SIGN and L-SIGN.  Inhibition of this interaction between E2 and the cell-
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surface receptors has therefore been identified as a possible target for designing anti-HCV 
molecules. 
Several groups have designed small molecules that inhibit binding of HCV-E2 to CD81 
(10, 11).  Molecules with bis-imidazole scaffold as mimics of helix D of CD81 were found to 
inhibit binding of HCV-E2 to CD81 (11).  A variety of amine complexes with 1-boraadamatane, 
namely, amantidine analogues showed antiproliferative effect on CD81-enriched cell lines (12).  
Recently, an oral antiviral arbidol, an indole derivative has been shown to inhibit HCV entry via 
HCV pseudoparticles (HCVpp).  Arbidol inhibited HCVpp-mediated membrane fusion in a dose-
dependent manner in different HCV genotypes, namely, 1a, 1b, and 2a (13).  Furthermore, 
carbohydrate-binding agents (CBAs) derived from different prokaryotic and plant lectins have 
antiviral activity due to their carbohydrate-binding properties.  These agents interact with the 
viral envelope glycoprotein and efficiently prevent the HCV entry process (14). 
Two peptides derived from cyanobacterium and human lactoferrin (LF) have been 
reported as HCV entry inhibitors (15, 16).  Cyanovirin-N, a 101-residue peptide (11 kDa), from 
cyanobacterium Nostoc ellipsosporum has been shown to inhibit HCV entry by binding to the 
envelope protein.  Cyanovirin-N shows broad inhibitory effect against various genotypes in 
nanomolar concentrations.  The mode of action is thought to be through interaction with N-
glycans of the E2 protein preventing E2 binding to the CD81, consequently blocking HCV entry 
to the target cell (15).  Another peptide derived from the C-terminal region of human LF showed 
binding activity to HCV-E2, leading to the inhibition of HCV infection in the target cells (16).  
Using a cell-based assay, it was shown that 33-residue LF fragment or Nozaki peptide (Figure 1) 
specifically prevented HCV infection in human hepatocytes.  Furthermore, the Nozaki peptide 
did not bind the hyper variable region (HVR-1) located at the N-terminal of E2 protein (384-
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415).  The authors demonstrated that the mechanism of action of this peptide fragment is by 
binding to the E2 protein of HCV, thereby blocking its entry into the host cell, rather than 
binding to the host cell-surface receptors (16).  The Nozaki peptide, however, was found to 
possess weaker E2-protein binding activity and anti-HCV activity to that of human LF. 
 
Figure 1:  (A) Three-dimensional structure of 33-residue lactoferrin-derived peptide 
(600-632 amino acids) obtained from the crystal structure of recombinant human 
lactoferrin (pdb 1CB6) (17).  Structure is shown as a ribbon diagram highlighting the 
helical (red) secondary structure.  (B) Amino acid sequence of the 33-residue 
lactoferrin-derived peptide.  Helical residues are underlined.  
 
We have studied five peptides (1-5, Figure 2) derived from the C-terminal region of LF 
sequence based on the results of Nozaki and coworkers (16).  These peptides were designed to 
identify a lead peptide with stronger binding affinity to E2.  E2 from HCV genotype 1b was 
expressed in mammalian cells and purified using affinity chromatography.  The results of the 
binding affinity between peptides 1-5 and the E2 protein, as well as, their mechanism of binding 
are reported here. 
 
Figure 2:  Sequence of five lactoferrin-derived peptides synthesized and studied 
herein.  Residues that are underlined indicate a change from the native lactoferrin 
sequence.  Nle stands for norleucine and b denotes biotin covalently linked to the N-
terminus of the peptides. 
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Results and Discussion 
Design and Synthesis of Peptide Ligands 
It was observed from the three-dimensional crystal structure of recombinant lactoferrin 
(17) that the 33-residue LF fragment or the Nozaki peptide is present on the surface of the 
protein.  Furthermore, the crystal structure shows that the 33 amino acid region (aa 600-632) 
consists of a central helical region (aa 607-620) and two flexible loops on the sides as shown in 
Figure 1.  Based on these observations, we decided to synthesize peptides containing the central 
helical region (i) with both the N- and C-terminal loops, (ii) with the C-terminal loop, and (iii) 
without loops (Figure 2).  Peptide 1, a 33-residue peptide with the central helical region and both 
the loops, is same as the Nozaki peptide except with a mutation at methionine 604 and with 
biotin (MW 361) covalently attached at the N-terminus.  In contrast, the Nozaki peptide has 
maltose-binding protein (MW 44000) covalently attached to it.  Peptides 2 and 3, consisting of 
27 and 17 amino acids, have either N-terminal loop or both N- and C-terminal loops deleted, 
respectively.  Finally, peptides 4 and 5 were designed with binding enhancing mutations (16).  
Peptides 4 and 5 are same as peptides 1 and 2 but with two mutations each, namely, S626A and 
D630A. 
Peptides 1-5 (Figure 2) derived from the C-terminal region of human lactoferrin were 
synthesized manually on Wang resin using standard Fmoc solid-phase peptide synthesis (SPPS) 
as described previously (18).  HBTU or BOP and HOBt were used as coupling agents.  For 
peptides 1 and 4, methionine (Met) was replaced by norleucine (Nle) in order to avoid any 
oxidation problems.  After the final N-terminal Fmoc amino acid was coupled to the peptide-
resin, the Fmoc group was removed and the N-terminus was biotinylated as described in the 
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Methods section.  Crude peptides were purified on a semi-preparative reversed-phase HPLC 
column by either isocratic or a gradient elution method using acetonitrile and water as solvents.  
The mass of the crude and pure peptides were confirmed by MALDI-TOF mass spectrometry.  
Purity of the peptides was confirmed by analytical reversed-phase HPLC and mass spectrometric 
analysis.  The yield of the purified peptides ranged between 50-65%.  The biotinylated peptides 
were used to develop a biotin-streptavidin based binding assay for the evaluation of binding 
affinity of these peptides toward the E2 envelope protein. 
 
Expression and Purification of E2 glycoprotein 
The HCV envelope E2 glycoprotein, exposed on the surface of virions, is likely to be 
involved in the interactions with the host and has been identified as responsible for binding of 
HCV to target cells (19).  HCV-E2 binds with high affinity to target cells only when expressed in 
mammalian cells, which is most likely due to the N-glycosylation and conformational changes it 
undergoes when expressed specifically in mammalian cells.  To study interaction of E2 protein 
with the synthesized peptide ligands, we expressed the extracellular (soluble) domain of E2, 
corresponding to aa 384-661 of isolate N2 (1b subtype) fused to a six-histidine tag at the C-
terminus.  Human embrionic kidney (HEK) 293 cells were transfected with plasmid vector 
E2N2661 using Lipofectamine 2000, and the protein was harvested after 48 hr.  The expected 
molecular weight of the glycosylated E2 protein is in the range of 62-66 kDa depending on 
glycosylation sites (20).  Western blot analysis of the expressed protein suggested the expression 
of E2 protein with MW ~63 kDa (Figure 3). 
The expressed E2 protein contains a His tag at the C terminus which facilitates 
purification using a nickel nitrilotriacetic acid (Ni2+-NTA) resin column.  The crude cell lysate 
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containing the His-tagged E2 protein was incubated with the Ni2+-NTA resin allowing non-
covalent binding of the protein to the resin.  The resin was then washed thoroughly to remove 
any unbound impurities and the pure protein was eluted with high concentration of imidazole 
(300 mM, elution buffer).  The Western blot analysis using anti-E2-mAb and anti-His6-mAb 
showed that the fractions 3-8 contained pure protein (Figure 3).  These six fractions containing 
the highest concentrations of the pure protein were combined and dialyzed against PBS to obtain 
7.8 mL of E2 with a concentration of 16.6 μg/mL. 
 
Figure 3:  E2N purification: Western blot analysis of the fractions obtained from the 
IMAC column, probed with mouse anti-His6 (1:1000) (left) and mouse anti-E2 
(1:20) (right) monoclonal antibodies.  CL: crude lysate; FT: flow through; 3-8: 
fractions 3-8 obtained using the elution buffer. 
 
Binding of Lactoferrin-derived Peptides to E2 Protein 
A biotin-streptavidin based binding assay was developed to access the binding affinity of 
the lactoferrin-derived synthetic peptides for E2 glycoprotein.  In this assay, biotin-labeled 
peptides bind to E2 protein allowing detection of the E2-bound peptides using a strepavidin-
horseradish peroxidase (Strep-HRPO) conjugate.  At the end of the assay, absorbance of the 
TMB substrate for Strep-HRPO is observed at 650 nm.  All the five peptides (1-5) displayed 
concentration-dependent response of peptide binding to E2 protein.  During the assays, biotin 
without the peptide was used as a control.  Biotin (4-40 M) showed no binding to the E2 
protein.  Also, peptides 1-5 did not bind to BSA when used as a control protein.  For each 
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peptide, the binding assay was repeated at least 3-4 times.  It was suggested by Nozaki et al. that 
the lactoferrin-derived peptides bind to a single site on the surface of the E2 protein (16).  Based 
on this hypothesis, it was assumed that all the peptides will display binding curves following the 
Scheme 1, 
 
 
 
where P = E2 protein, L = ligand or peptide, and PL = noncovalent protein-peptide adduct.  
Initial glance at the binding curves showed that peptides 3 and 5 displayed an exponential rise in 
absorbance with increasing peptide concentration (Figure 4).  However, peptides 1, 2, and 4 
displayed a more complex mechanism of binding.  These peptides show an initial lag in the 
binding curve suggesting non-specific binding or multiple binding sites for the peptide ligands 
on E2 protein (Figure 5). 
 
Figure 4:  Binding of E2 protein to peptides 3 (top) and 5 (bottom). Shown is 
absorbance of TMB substrate at 650 nm as a function of different peptide 
concentration.  The symbols are experimental data points whereas the line was 
calculated by fitting the data to Scheme 1 as described in the text. 
 
Accordingly, the data for peptides 3 and 5 were fitted to Scheme 1 to obtain the 
hyperbolic curves as shown in Figure 4.  The fitted curves and the values for the corresponding 
equilibrium dissociation constants (Kd) were obtained by the DynaFit program (21, 22) as 
P  +  L PL
Scheme 1
Kd dissoc.
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described previously (23).  DynaFit is a numerical simulation software that allows nonlinear 
least-squares regression of the equilibrium or kinetic data to obtain binding constants.  Using this 
program, Kd values of 28.8 ± 2.90 and 0.569 ± 0.0390M were obtained for peptides 3 and 5, 
respectively.  Peptide 5 with two mutations (S626A and D630A) displayed better binding profile 
compared to all other peptides including the 33 residue peptide 1.  Single mutation of S626 or 
D630 to alanine in the 33 residue Nozaki peptide was previously found to enhance binding 
affinity.(16)  Our results further confirm that these mutations augment binding activity. 
 
Figure 5:  Binding of E2 protein to peptides 1 (), 2 (), and 4 ().  Shown is 
absorbance of TMB substrate at 650 nm as a function of different peptide 
concentration.  The symbols are experimental data points whereas the line is drawn 
to guide the eye. 
 
Circular Dichroism of -Peptides 
Circular dichroism (CD) spectroscopy was used to evaluate the secondary structure of the 
synthetic peptides in solution.  CD spectra were obtained for three different concentrations (25, 
50, and 100 µM) in phosphate buffer (pH 7.4) for each peptide.  The spectra were found to be 
independent of concentration suggesting no aggregation in this concentration range.  In all the 
peptides, helical structure was induced indicated by the appearance of distinct negative bands at 
206-207 nm and negative shoulders near 220 nm.  The CD spectra were analyzed using CDPro 
software (24) to obtain relative ratio of different secondary structures present as described 
previously (Table 1) (18).  Quantitative analysis of the distribution of secondary structure 
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showed that peptides 3 and 5 have high helical content of 38 and 71%, respectively.  Both the 
33-residue peptides, 1 and 4, displayed similar secondary structure with about 32-34% -helix.  
Surprisingly, peptide 2 with 27 amino acids, same length as peptide 5, showed substantial loss of 
the -helical structure.  The helical conformation (44% helical) in 2 could be induced in the 
presence of 50% trifluoroethanol.  It is, however, noteworthy that peptides 3 and 5 have the 
highest helical content (Table 1), with 5 exhibiting greater helicity than 3.  This helical region 
may be crucial for binding as pointed out by Nozaki and coworkers (16).  The binding affinity 
(Kd) of 5 and 3 was 0.569 M and 28.8 M, respectively.  This suggests that increasing the 
helical content or stabilizing the helical conformation may lead to enhanced binding activity. 
 
Table 1:  CD Analysis of the Secondary Structure Fractions of Peptides 1-5 in PBS at 
25 C. 
 
Peptides 1-5 derived from LF contain several charged and polar residues with an overall 
charge of +3 or +4.  The -helical wheel representation of peptide 5 shows that the peptide is 
amphipathic with a polar/hydrophilic and hydrophobic face (Figure 6).  This was further 
supported by the very high amphipathicity value of 7.65 for peptide 5.  Amphipathicity was 
determined by the calculation of hydrophobic moment (25) using the software package Jemboss 
version 1.5 (26).  The amphipathic nature of the peptide suggests that the predominant 
interaction involved between the peptide and E2 is electrostatic and hydrogen bonding 
interaction.  Further, it is presumed that peptides 1-5 do not bind the hypervariable region 1 
region (aa 384-410) of the E2 protein, since the 33-residue Nozaki peptide preferentially bound 
to aa 411-500 of the E2 protein (16).  This binding site on E2 also seems different from the 
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CD81 binding site.  CD81 is known to recognize aa 480-493 and aa 544-551 of the E2 protein 
(27).  E2 is a heavily glycosylated protein and its three-dimensional structure is not yet 
elucidated (28, 29).  Therefore, the spatial relationship between the LF-derived peptides and E2 
binding site is not known.  It is however clear from our binding assay results that 3 and 5 bind on 
a single site on E2.  Peptides 1, 2, and 4 may bind on multiple sites on E2 protein indicated by 
the different binding rate constants.  These multiple sites could be in close proximity to the 
primary binding site, as tandem repeats of the Nozaki peptide were found to enhance binding 
activity (30).  Abe and coworkers found that the E2 binding activities of the two repeats (33-
residue Nozaki peptide)2 and the three repeats (33-residue Nozaki peptide)3 were stronger than 
the Nozaki peptide itself (30). 
 
Figure 6:  Edmundson -helical wheel representation of peptide 5.  The solid curve 
indicates the polar/hydrophilic face and the dashed curve denotes hydrophobic face. 
 
Evaluation of a relatively small number of -peptides has allowed identification of potent 
and specific binders of E2 that are suitable candidates for further investigation.  These peptides 
are currently being evaluated using a cell-based anti-HCV assay and will serve as lead molecules 
for the design of future peptide-based or peptidomimetic libraries.  Such molecules, useful for 
the elimination of circulating HCV, can be used as prophylactic alone or in combination with 
other anti-HCV agents.  It has been suggested that a cocktail of drugs targeting multiple steps of 
the HCV life-cycle will be required to treat chronic hepatitis C (31). 
In summary, we have reported five peptides (1-5) derived from LF sequence that bind to 
E2 protein from the N strain of HCV in a concentration-dependent manner.  Two of the peptides 
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identified, 3 and 5, bind E2 with submicromolar to micromolar affinity.  These two peptides are 
smaller in length than the starting 33-residue LF-derived peptide, and contain the central helical 
region from the parent peptide.  Further, among the five peptides evaluated for binding E2, 3 and 
5 had the highest helical content (38% and 71%, respectively) demonstrating the importance of 
helical secondary structure for binding.  These peptides will serve as lead for our future 
investigations of HCV entry inhibitors.  Based on these results, several libraries of peptides and 
peptidomimetics are currently being designed and synthesized that will serve as tools for 
understanding the molecular basis of E2 and cell surface receptor interactions, and may lead to a 
feasible approach for the treatment and prevention of HCV infection. 
 
Materials and Methods 
All commercially available solvents and reagents were used without further purification.  
D-Biotin was purchased from Sigma Chemical Co. (St. Louis, MO, USA).  Wang resin and BOP 
were obtained from Novabiochem (San Diego, USA).  HOBT, HBTU, and Fmoc-protected 
amino acids were purchased from Peptides International (Louisville, USA).  RP-HPLC 
purification and analysis were carried out on a Waters (625 LC system) HPLC system using 
Vydac semi-preparative C18 (1 x 25 cm, 5 μm) and analytical C8 (0.46 x 25 cm, 5 μm) columns.  
Compounds were detected by UV absorption at 220 nm.  Mass spectra were recorded on a 
MALDI Voyager time-of-flight (TOF) spectrometer (VoyagerTM Elite). 
Plasmid vector E2N2661 (genotype 1b isolate N2), with a concentration of 10 g/L was 
provided by IRBM (Merck, Italy) (29).  Lipofectamine 2000, 0.05% Trypsin / EDTA, 
OptiMEM-I, and nitrocellulose membrane were purchased from Invitrogen (Carlsbad, Canada).  
Human embrionic kidney (HEK) 293 cells were obtained from American Type Tissue Culture 
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(Bethesda, MD, USA).  Kanamycin, bovine serum albumin (BSA), agarose, 2-mercaptoethanol, 
imidazole and Folin-phenol were purchased from Sigma Chemical Co. (St. Louis, MO, USA).  
Equipment and reagents for SDS-PAGE and Western blotting were from Bio-Rad (Mississauga, 
Canada).  Dulbecco's Modified Eagle's Medium (DMEM) and fetal bovine serum (FBS) were 
purchased from Gibco BRL (Burlington, Canada).  The anti-His6 mouse monoclonal antibody 
was purchased from Novagen (Madison, USA), whereas the anti-HCV-E2 mouse monoclonal 
antibody was purchased from ViroStat (Portland, ME).  Restriction endonucleases HindIII was 
obtained from Life Technologies (Burlington, Canada).  Plasmid Mega Kit, plasmid mini-
preparation kit and Ni–NTA–agarose resin was obtained from Qiagen (Mississauga, Canada).  
Enhanced chemiluminescence (ECL) immunodetection kits, antimouse horseradish peroxidase-
linked secondary antibodies and DNA molecular weight markers were purchased from 
Amersham Biosciences (Oakville, Canada).  TMB (3,3',5,5'-tetramethylbenzidine) substrate 
solution was obtained from KLP Laboratories (Gaithersburg, USA). 
 
Peptide Synthesis 
Stepwise synthesis of the peptides 1-5 was done manually on a 0.3-mmol scale of Wang resin 
(1.0% DVB cross-linked) following the standard Fmoc solid-phase peptide chemistry as 
described previously (18).  Fmoc protected L-amino acids were used and the following side 
chain protection was used: Boc (Lys), But (Ser, Thr), OBut (Asp, Glu), Trt (Asn, Cys, Gln, His), 
and Pbf (Arg).  A test cleavage was performed after each five residues were coupled and the 
desired product was confirmed by MALDI-TOF mass spectrometry. Each test peptide was 
cleaved from the resin with a mixture of 87.5% TFA, 5% phenol, 5% water, 2.5% DTT, and 
2.5% anisole for 90 minutes at room temperature with mechanical shaking. 
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After complete assembly of the peptide on the resin, the N-terminus was biotinylated by 
addition of biotin (0.5 mmol), DIC (0.5 mmol), and HOBT (0.5 mmol) in DMF to the resin.  The 
suspension was allowed to stir for 27 hours at room temperature.  Kaiser test was carried out to 
ensure complete biotinylation.  The biotinylated peptide was released from support, with 
concomitant removal of acid-labile side chain protecting groups using the same procedure as 
used for the test cleavages.  The filtrate from the cleavage reactions was collected, combined 
with TFA washes (3 x 2 min, 1 mL), and concentrated in vacuo. Cold diethyl ether (~ 15 mL) 
was added to precipitate the crude cleaved peptide.  After trituration for 2 min, the peptide was 
collected upon centrifugation and decantation of the ether. The crude peptide was dissolved in 
10-20% aqueous acetonitrile and purified on a semi-preparative VYDAC C18 reversed-phase 
HPLC column (10 x 250 mm, 5 m) using an acetonitrile/water (in the presence of 0.05% TFA, 
v/v) gradient (flow rate = 2 mL/min, monitored at 220 nm) over a period of 40 minutes.  The 
details of the gradient elution method used for purification of each peptide are listed in the Table 
1.  Purity of the peptides was confirmed by analytical reversed-phase HPLC and MALDI-TOF 
mass spectrometry (Table 1). 
 
Table 2:  The HPLC purification details for peptides 1-5. 
 
E2 Expression and Purification 
Human embrionic kidney (HEK) 293 cells were cultured in high-glucose Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum at 37 °C in 
a humidified 5% CO2 atmosphere.  Transfections using the E2N2661 plasmid vector (29) were 
performed in 6 well tissue culture plates with 20 g DNA per well using lipofectamine2000 
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reagent (Invitrogen) as per manufacturer’s instructions.  The cells were transfected at a density of 
1.5 x 105 cells per 0.6 mL per well and harvested two days after transfection at about 90% 
confluence in ice-cold lysis buffer [50 mM Tris pH 7.0, 1 M NaCl and 1 mM 
phenylmethylsulfonyl fluoride (PMSF) as protease inhibitor].  After centrifugation, the 
supernatant containing protein lysate was loaded onto 12% SDS-PAGE gel.  Prior to loading on 
the gels, the samples were treated by heating at 95 ˚C for 5 minutes in sample loading buffer (80 
mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 2%mercaptoethanol, 0.02% bromophenol 
blue).  Gel-separated proteins were electroblotted onto nitrocellulose membrane and the 
membrane was blocked overnight at 4 °C in 5% skim milk.  The membrane was washed with 
TBST followed by incubation with the mouse anti-His6 MAb (1:1000) or anti-E2 mAb (1:20) for 
1 h.  Subsequently the membrane was washed with TBST and incubated with goat anti-mouse 
horseradish peroxidase-linked secondary antibodies GAM–HRPO (1:10,000) for 1 h.  Following 
a final washing step, the binding of MAbs to antigen was detected using the enhanced 
chemiluminescence substrate (ECL). 
The crude cell lysate (CL) containing the His-tagged E2 protein was purified by 
immobilized metal affinity chromatography (IMAC) using a Ni2+-NTA resin column under 
denaturing conditions according to the protocol provided by the manufacturer (Qiagen).  Briefly, 
CL was incubated with Ni2+-NTA resin, and the suspension was incubated overnight at 4 °C with 
gentle rocking.  The resin was loaded on a column and equilibrated with 10 bed volumes of the 
lysis buffer (50 mM Tris–HCl, 1 M NaCl, pH 7.0).  It was then washed extensively with the 
washing buffers containing increasing amounts of imidazole in the buffer.  Finally, His-tagged 
protein was eluted using elution buffer (50 mM Tris–HCl, 1 M NaCl, and 300 mM imidazole, 
pH 7.0).  The pure protein and the CL were analyzed by SDS-PAGE and Western blot as 
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described above.  The concentration of the purified E2 was determined by the method of Lowry 
et al. using bovine serum albumin (BSA) as standard.(32)  Duplicates were prepared for both the 
standards and the experimental samples.  Experimental samples consisted of 50 μL of the 
purified E2 protein. 
 
Biotin-Streptavidin based Binding Assay 
A biotin-streptavidin based binding assay was developed to examine the binding affinity 
between the E2 protein and peptide ligands.  E2 (N strain) antigen (100 µL, 150 or 200 ng/well) 
in PBS (1 mM, pH 7.4) was added to the wells of a 96-well microtiter immunoplate and 
incubated overnight at 4 °C to allow the antigen to adsorb to the surface.  Excess antigen was 
removed from the plate by rinsing each well with 300 µL PBS (1 mM, pH 7.4) containing 0.05% 
Tween-20.  Subsequently the wells were blocked by incubating with 200 µL of 2% BSA in PBS.  
After discarding the supernatant, each well was washed with 0.05% Tween-20 in PBS.  Stock 
solutions of peptides 1-5 were prepared and concentrations were determined by Lowry 
assay.(32)  Biotin was used as a control.  Peptide solution or biotin (100 µL/well) was added to 
each well in duplicates and the plate was incubated at room temperature on a shaker (200 rpm) 
for 3 h.  The supernatant was discarded and the wells were rinsed with 0.05% Tween-20 in PBS.  
To each well was then added a solution (100 L) of Strep-HRPO (0.1 g) in 1% BSA and the 
plate was incubated at room temperature for 1 h while gently agitating on a shaker.  After 
discarding the Strep-HRPO solution, plate was rinsed with 0.05% Tween-20 in PBS (300 µL x 3) 
and TMB substrate solution (100 L, TMB Peroxidase:Peroxidase solution B, 1:1, v/v) was 
added  to each well.  The plate was then incubated at room temperature for about 15 minutes 
until the absorbance reached an appropriate level (0.7-0.8).  The absorbance in each well was 
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measured using ELISA Vmax kinetic microplate reader (Molecular Devices Corp., CA, USA) at 
650 nm.  The equilibrium absorbance data for each peptide was plotted against peptide 
concentration.  For peptides 3 and 5, the absorbance data was fitted to Scheme 1 using the 
numerical simulation/least-squares fitting program Dynafit (21). 
 
Circular Dichroism (CD) Spectroscopy 
All CD measurements were made on an Olis CD spectrometer (Georgia, USA) at 25 °C 
in a thermally controlled quartz cell with a 0.02 cm path length over 190-260 nm.  The peptide 
stock solutions were diluted with phosphate buffer (1 mM, pH 7.0) to give final concentrations 
of 25, 50, and 100 μM for CD measurements.  Data were collected every 0.05 nm and were the 
average of 10 scans.  The bandwidth was set at 1.0 nm and the sensitivity at 50 mdeg, and the 
response time was 0.25 s.  In all cases baseline scans of aqueous buffer were subtracted from the 
experimental readings.  Results were expressed in units of molar ellipticity per residue (deg cm2 
dmol-1) and plotted versus wavelength.  Analysis of the CD spectra involved quantitative curve 
fitting using the CDPro software analysis program (24) as described previously (18).  Briefly, the 
software uses three programs to perform the protein secondary structure analysis from CD 
spectra. Output data from each of the three programs provide fractions of six different secondary 
structure classes, namely regular -helix, distorted -helix, regular -strand, distorted -strand, 
turns, and unordered.  Since the same set of reference protein was used by each of the three 
programs, their fractional secondary structures could be averaged.  For convenience of data 
interpretation, the regular and distorted components of -helix and -strand, and turns and 
unordered structural elements were added to give overall helical, strand, and coil structures, 
respectively.  The final secondary structure elements were the average from the triplicate 
 19 
samples for each peptide and the standard error was calculated for each of them.  Each was also 
examined separately using the three analysis programs mentioned above and the standard error 
was calculated for each of them.  The latter results are all within the experimental error given. 
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TABLES 
 
 
 
 
 
 
Table 1:  CD Analysis of the Secondary Structure Fractions of Peptides 1-5 in PBS at 25 C 
 
Peptidea Number of 
residues 
-helixb  
± SEM 
-sheetb  
± SEM 
coilb  
± SEM 
     
1 33 0.32 ± 0.03 0.20 ± 0.002 0.48 ± 0.03 
2 27 0.12 ± 0.06 0.35 ± 0.04 0.53 ± 0.02 
3 17 0.38 ± 0.04 0.15 ± 0.04 0.47 ± 0.05 
4 33 0.34 ± 0.02 0.16 ± 0.01 0.51 ± 0.007 
5 27 0.71 ± 0.01 0.05 ± 0.002 0.23 ± 0.009 
     
a All samples were prepared three times in PBS (10 mM, pH 7.0).  Samples 
were allowed to equilibrate for at least 10 min at 25 C before taking CD 
scans..  bSecondary structure determination from CD data was done using 
CDPro software (24) as described in the Experimental Section. 
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Table 2:  The HPLC purification details for peptides 1-5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide Mass [M+H]+ 
Observed (Calcd.) 
Solvent used for HPLC 
purification 
Elution 
time 
(min) 
Pure 
Yield 
1 4040 (4039) 10-45% acetonitrile/H2O 22.3 50% 
2 3370 (3369) 30% acetonitrile/H2O 12.8 55% 
3 2249 (2249) 10-40% acetonitrile/H2O 35.5 65% 
4 3980 (3979) 20-65% acetonitrile/H2O 33.1 56% 
5 3309 (3309) 20-65% acetonitrile/H2O 29.8 52% 
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FIGURE LEGENDS 
 
 
Figure 1:  (A) Three-dimensional structure of 33-residue lactoferrin-derived peptide (600-632 
amino acids) obtained from the crystal structure of recombinant human lactoferrin (pdb 1CB6) 
(17).  Structure is shown as a ribbon diagram highlighting the helical (red) secondary structure.  
(B) Amino acid sequence of the 33-residue lactoferrin-derived peptide.  Helical residues are 
underlined. 
 
Figure 2:  Sequence of five lactoferrin-derived peptides synthesized and studied herein.  
Residues that are underlined indicate a change from the native lactoferrin sequence.  Nle 
stands for norleucine and b denotes biotin covalently linked to the N-terminus of the peptides. 
 
Figure 3:  E2N purification: Western blot analysis of the fractions obtained from the IMAC 
column, probed with mouse anti-His6 (1:1000) (left) and mouse anti-E2 (1:20) (right) 
monoclonal antibodies.  CL: crude lysate; FT: flow through; 3-8: fractions 3-8 obtained using the 
elution buffer. 
 
Figure 4:  Binding of E2 protein to peptides 3 (top) and 5 (bottom). Shown is absorbance of 
TMB substrate at 650 nm as a function of different peptide concentration.  The symbols are 
experimental data points whereas the line was calculated by fitting the data to Scheme 1 as 
described in the text. 
 
Figure 5:  Binding of E2 protein to peptides 1 (), 2 (), and 4 ().  Shown is absorbance of 
TMB substrate at 650 nm as a function of different peptide concentration.  The symbols are 
experimental data points whereas the line is drawn to guide the eye. 
 
Figure 6:  Edmundson -helical wheel representation of peptide 5.  The solid curve indicates the 
polar/hydrophilic face and the dashed curve denotes hydrophobic face. 
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